首页> 美国卫生研究院文献>Annals of Oncology >Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

【2h】

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期临床试验：滤泡性淋巴瘤国际预后指数（FLIPI）评分可预测前期免疫疗法的反应性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThis phase II CALGB trial evaluated the activity and safety of an extended induction schedule of galiximab (G) plus rituximab (R) in untreated follicular lymphoma (FL).

机译：背景这项CALGB II期试验评估了未治疗的滤泡性淋巴瘤（FL）中加利昔单抗（G）加利妥昔单抗（R）延长诱导方案的活性和安全性。

著录项

期刊名称 Annals of Oncology
作者
M. S. Czuczman; J. P. Leonard; S. Jung; J. L. Johnson; E. D. Hsi; J. C. Byrd; B. D. Cheson;
展开▼
作者单位

展开▼
年(卷),期 -1(23),9
年度 -1
页码 2356–2362
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
follicular lymphoma Follicular Lymphoma International Prognostic Index (FLIPI) galiximab immunotherapy monoclonal antibodies rituximab;

机译：滤泡性淋巴瘤;滤泡性淋巴瘤国际预后指数（FLIPI）;加利昔单抗;免疫疗法;单克隆抗体;利妥昔单抗;

相似文献

外文文献
中文文献

1. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness (vol 23, pg 2356, 2012) [J] . Czuczman M. S., Leonard J. P., Jung S., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第11期

机译：Galiximab的II期试验（抗CD80单克隆抗体）加里妥昔单抗（CalgB 50402）：卵泡淋巴瘤国际预后指数（FLIPI）评分是预测前期免疫治疗响应性（第23卷，PG 2356,2012）
2. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular lymphoma international prognostic index (FLIPI) score is predictive of upfront immunotherapy responsiveness [J] . CzuczmanM.S., LeonardJ.P., JungS., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第9期

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期试验：滤泡性淋巴瘤国际预后指数（FLIPI）得分可预测前期免疫疗法的反应性
3. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness [J] . M. S. Czuczman1* J. P. Leonard2 S. Jung3 J. L. Johnson3 E. D. Hsi4 J. C. Byrd5 and B. D. Cheson6 Annals of Oncology . 2012,第9期

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期试验：滤泡性淋巴瘤国际预后指数（FLIPI）评分可预测前期免疫疗法的反应性
4. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness [O] . M S Czuczman, J P Leonard, S Jung, -1

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期临床试验：滤泡性淋巴瘤国际预后指数（FLIPI）评分可预测前期免疫疗法的反应性
5. Corrections to “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness” [O] . M.S. Czuczman, J.P. Leonard, S. Jung, 2018

机译：矫正“Galiximab的第二阶段试验”（抗CD80单克隆抗体）加里妥昔单抗（CalgB 50402）：卵泡淋巴瘤国际预后指数（FLIPI）评分是预测前期免疫治疗响应性“

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

摘要

著录项

相似文献

相关主题

期刊订阅